外刊泛读｜拥有自主知识产权的中国“人工肺”上市！

原文标题：

China’s ’artificial lung’ with independent intellectual property rights comes on market

部分节选：

China Aerospace Science and Technology Corporation and Peking Union Medical College Hospital jointly announced on Wednesday that their new “artificial lung” with fully independent intellectual property rights has come onto the market in Beijing.

Their ECMO (extracorporeal membrane oxygenation) system is also commonly known as an “artificial lung.” The ECMO machine is similar to a heart-lung bypass machine used in open-heart surgery. It pumps and oxygenates a patient’s blood from outside the body, allowing the heart and lungs to rest.

Their ECMO (extracorporeal membrane oxygenation) system is also commonly known as an “artificial lung.” The ECMO machine is similar to a heart-lung bypass machine used in open-heart surgery. It pumps and oxygenates a patient’s blood from outside the body, allowing the heart and lungs to rest.

他们的ECMO(体外膜氧合)系统通常也被称为“人工肺”ECMO机器类似于心内直视手术中使用的心肺旁路机。它从体外泵送和氧合病人的血液，使心脏和肺部得到休息。

The whole machine, called Huisheng-I ECMO, weighs about 7.5 kilograms, less than half the weight of similar foreign products, so it can better meet the emergency and transport needs of critically ill patients.

The whole machine, called Huisheng-I ECMO, weighs about 7.5 kilograms, less than half the weight of similar foreign products, so it can better meet the emergency and transport needs of critically ill patients.

这款名为“惠生-I ECMO”的整机重约7.5公斤，不到国外同类产品重量的一半，因此可以更好地满足危重病人的急救和运输需求。

ECMO is an important part of life support for patients, as well as an important treatment means to gain time for them. However, the technical threshold is high, as is the price, and the key core technologies have previously been monopolized by a few multinational medical device enterprises.

ECMO is an important part of life support for patients, as well as an important treatment means to gain time for them. However, the technical threshold is high, as is the price, and the key core technologies have previously been monopolized by a few multinational medical device enterprises.

ECMO是患者生命支持的重要组成部分，也是为患者赢得时间的重要治疗手段。但技术门槛高，价格也高，关键核心技术此前被少数跨国医疗器械企业垄断。

The development of China’s ECMO system has broken the monopoly of foreign enterprises, improved the access to advanced life support equipment in China, and significantly reduced the price of the product, which is conducive to reducing the burden of medical treatment for patients.

The development of China’s ECMO system has broken the monopoly of foreign enterprises, improved the access to advanced life support equipment in China, and significantly reduced the price of the product, which is conducive to reducing the burden of medical treatment for patients.

中国ECMO系统的发展打破了国外企业的垄断，提高了先进生命支持设备在中国的获取渠道，大幅降低了产品价格，有利于减轻患者的就医负担。

中国ECMO系统的发展打破了国外企业的垄断，提高了先进生命支持设备在中国的获取渠道，大幅降低了产品价格，有利于减轻患者的就医负担。